Skip to main content

Table 3 Immunohistochemical characteristics and their association with loss of wt BRCA1 in ER-positive and ER-negative BRCA1-related breast cancers

From: Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

Variable ER+ ER-
  Loss of wt BRCA1N(%) No loss of wt BRCA1N(%) P-value Loss of wt BRCA1N(%) No loss of wt BRCA1
N(%)
P-value
Cytokeratins       
CK5/6 (31) (7) 0.164 (27) (4) 0.010
   Positive 9 (29.0) 0   20 (74.1) 0  
   Negative 22 (71.0) 7 (100)   7 (25.9) 4 (100)  
CK7/8 (31) (8) --- (28) (4) 1.0
   Positive 31 (100) 8 (100)   25 (89.3) 4 (100)  
   Negative 0 0   3 (10.7) 0  
CK14 (31) (6) 0.566 (27) (3) 0.054
   Positive 5 (16.1) 0   18 (66.7) 0  
   Negative 26 (83.9) 6 (100)   9 (33.3) 3(100)  
CK5/6 or CK14 (33) (8) 0.083 (27) (4) 0.001*
   Positive 11 (33.3) 0   24 (88.9) 0  
   Negative 22 (66.7) 8 (100)   3 (11.1) 4 (100)  
CK 18 (32) (7) ---- (27) (4) 1.00
   Positive 32 (100) 7 (100)   26 (96.3) 4 (100)  
   Negative 0 0   1 (3.7) 0  
CK19 (33) (6) ---- (28) (4) 0.125
   Positive 33 (100) 6 (100)   28 (100) 3 (75)  
   Negative 0 0   0 1 (25)  
EGFR (30) (7) 0.560 (26) (4) 0.360
   Positive 5 (16.7) 0   24 (92.3) 3(75)  
   Negative 25 (83.3) 7 (100)   2 (7.7) 1 (25)  
CK5/6 and/or CK14 and/or EGFR (33) (8) 0.083 (28) (4) 0.125
   Positive 11 (33.3) 0   28 (100) 3 (75)  
   Negative 22 (66.7) 8 (100)   0 1 (25)  
P53 (30) (7) 1.00 (26) (4) 0.601
   Positive 14 (46.7) 4 (57.1)   13 (50) 3 (75)  
   Negative 16 (53.3) 3 (42.9)   13 (50) 1 (25)  
  1. Abbreviations: ER, estrogen receptor; CK, cytokeratin; EGFR, epidermal growth factor receptor.
  2. Loss of wt: cancers with LOH with loss of wt BRCA1 allele.
  3. No loss of wt: includes cancers with no LOH and LOHmut .
  4. *P-value retained significance with Bonferroni adjustment for multiple comparisons.
  5. Percentages calculated by column.